Physician profile
Rahul Dutta
NPI 1770080368
$13,233.24
in general payments reported to CMS, 2019-2025
10 companies · $784 in 2025
The $784 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $349 · 2022: $331 · 2023: $652 · 2024: $11K · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $10K · Food and Beverage: $2,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $10,000.00 |
| Food and Beverage | $2,552.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,213.76 | 2023-2025 | Interstim |
| Boston Scientific Corporation | $1,049.82 | 2021-2025 | Ams 700, Ams Ambicor, Ams 700 Cxr Rte Kit |
| Coloplast Corp | $220.49 | 2024 | |
| Axonics, INC. | $171.69 | 2024 | Axonics |
| Avanos Medical | $169.26 | 2021 | |
| Sumitomo Pharma America, INC. | $131.65 | 2025 | Gemtesa |
| Ambu INC. | $117.82 | 2023 | |
| Olympus America INC. | $103.68 | 2021 | |
| Innovation Technologies INC | $38.89 | 2025 | Irrisept |
| Bluewind Medical | $16.18 | 2024 | Revi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Dutta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.